AbbVie reportedly claims that Genmab and its recent acquisition, ProfoundBio, knowingly participated in the misappropriation ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees helped ProfoundBio use confidential tech to improve its cancer treatment ...

Genmab A/S (Nasdaq: GMAB) announced today that AbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

AbbVie sues Genmab's ProfoundBio for allegedly stealing trade secrets in developing rinatabart sesutecan, a potential rival to ovarian cancer drug Elahere. Genmab said it ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously ...